Successful treatment of two cases with Philadelphia-chromosome positive acute lymphoblastic leukemia who relapsed after allogeneic stem cell transplantation and the treatments with novel immunotherapies and ponatinib

Figures & data

Figure 1. Overall Clinical courses of two patients with Ph+ALL Dx, diagnosis; uBMT, unrelated bone marrow transplantation; CBT, umbilical cord blood transplantation; CAR-T, chimeric antigen receptor T-cell therapy; Pon, ponatinib; BLN, blinatumomab; InO, inotuzumab ozogamicin; Clo, clofarabine; NR, non-remission, CR, complete remission; MRD, measurable residual disease; CT, chemotherapy.

Figure 2. Detailed treatment managements in critical phases for Case 1 (a) and Case 2 (b). CAR-T, chimeric antigen receptor T-cell therapy; Pon, ponatinib; InO, inotuzumab ozogamicin; MA, methotrexate plus cytarabine; Cy, cyclophosphamide; flu, fludarabine; MRD, measurable residual disease for BCR-ABL1 mRNA; Clo, clofarabine; CBT, umbilical cord blood transplantation; Mel, melphalan; TBI, total body irradiation; WBC, white blood cell count; Plt, platelet.